Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib in Refractory SPOP-Mutant Prostate Cancer
NCT05828082Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tuvusertib in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
tuvusertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05828082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828082.